|Bid||33.20 x 1000|
|Ask||33.19 x 1100|
|Day's Range||33.07 - 34.09|
|52 Week Range||31.62 - 104.50|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.06|
Subscribe to Yahoo Finance Plus to view Fair Value for EXAS
With inflation, rising interest rates, and fear of a recession weighing on investors' minds, even the best stocks have been in freefall. Investment bank analysts on Wall Street have identified a handful of top growth stocks that have a lot more potential than their present market values would suggest. Wall Street analysts who follow Exact Sciences think its best days are still to come.
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.